TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21494170

Group type: EXPERIMENTAL
Intervention: Interactive training model (group A)
Number of subjects: 1282

Group type: EXPERIMENTAL
Intervention: Lecture-based training model (group B)
Number of subjects: 1282

Group type: EXPERIMENTAL
Intervention: Video instruction training model (group C)
Number of subjects: 1282
Study: 18313556

Group type: EXPERIMENTAL
Intervention: Sequential designs (group sequential designs, boundaries designs, adaptive designs)
Number of subjects: 0
Study: 17201235

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide instillation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Topical administration of betamethasone
Number of subjects: 24
Study: 14690186

Group type: EXPERIMENTAL
Intervention: Continuous intravenous SonoVue contrast echocardiography
Number of subjects: 11

Group type: COMPARATOR
Intervention: Intermittent harmonic B-mode imaging
Number of subjects: 11
Study: 11310114

Group type: EXPERIMENTAL
Intervention: 633 nm laser source with a 3 kHz bandwidth filter using a probe with a 500 microns fibre separation placed 2‐3 mm from the gingival margin
Number of subjects: 10

Group type: COMPARATOR
Intervention: non-vital tooth
Number of subjects: 10
Study: 8830396

Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound (HIFU)
Number of subjects: 32
Study: 1638306

Group type: EXPERIMENTAL
Intervention: Minaprine (200 mg daily)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Amitriptyline (25-50 mg t.d.s.)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 144
Study: 6701732

Group type: EXPERIMENTAL
Intervention: Crystalloid (RL)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Colloid (5% ALB)
Number of subjects: 46
Study: 29370407

Group type: EXPERIMENTAL
Intervention: e‐coaching (automated program of 45 e‐mails over 3 months)
Number of subjects: 2478

Group type: COMPARATOR
Intervention: booklet (PDF version of a smoking cessation booklet)
Number of subjects: 2478

Group type: EXPERIMENTAL
Intervention: e‐coaching (per-protocol sample)
Number of subjects: 2478
Study: 29766294

Group type: EXPERIMENTAL
Intervention: Beetroot (BR) juice (140 mL/day, containing 8 mmol of nitrate)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PL) juice (140 mL/day, containing 0.003 mmol of nitrate)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Beetroot (BR) juice
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PL) juice
Number of subjects: 8
Study: 26194850

Group type: EXPERIMENTAL
Intervention: Iron-Folic Acid (IFA)
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Multiple Micronutrients (MMN)
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Lipid-Based Nutrient Supplements (LNS)
Number of subjects: 1391

Group type: COMPARATOR
Intervention: Comparison of MMN to IFA
Number of subjects: 1391

Group type: COMPARATOR
Intervention: Comparison of LNS to IFA
Number of subjects: 1391
Study: 24240632

Group type: EXPERIMENTAL
Intervention: Childcare/kindergarten attendees
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Swimming in public pools/spas in the current or previous week
Number of subjects: 277
Study: 22978102

Group type: EXPERIMENTAL
Intervention: Qianggu Granule (QGG)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diacerein Capsule (DC)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Qianggu Granule (QGG) + Diacerein Capsule (DC)
Number of subjects: 90
Study: 20576731

Group type: EXPERIMENTAL
Intervention: Doxycycline in addition to systemic corticosteroids
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 205
Study: 17926797

Group type: EXPERIMENTAL
Intervention: Sunitinib malate (Sutent)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sorafenib tosylate (Nexavar)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin)/interferon alfa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temsirolimus (Torisel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 0
Study: 16241976

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) therapy
Number of subjects: 0
Study: 12933923

Group type: EXPERIMENTAL
Intervention: IVMP with planned multidisciplinary team (MDT) care
Number of subjects: 40

Group type: COMPARATOR
Intervention: IVMP with standard care
Number of subjects: 40
Study: 10657819

Group type: EXPERIMENTAL
Intervention: Exercise group (10 tuck jumps 3 times weekly, jumping, hopping, and skipping incorporated into twice weekly physical education classes)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (regular physical education classes)
Number of subjects: 144
Study: 8896159

Group type: EXPERIMENTAL
Intervention: Haemaccel
Number of subjects: 20

Group type: COMPARATOR
Intervention: human albumin
Number of subjects: 20
Study: 1714532

Group type: EXPERIMENTAL
Intervention: Ondansetron plus dexamethasone
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ondansetron plus placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combination therapy (ondansetron plus dexamethasone)
Number of subjects: 31
Study: 6357270

Group type: EXPERIMENTAL
Intervention: Weekly cardiotocography (antenatal fetal heart rate monitoring)
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Abnormal antenatal fetal heart rate traces
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Monitoring
Number of subjects: 539
Study: 30747010

Group type: EXPERIMENTAL
Intervention: Accelerated physiotherapy programme
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard physiotherapy programme
Number of subjects: 80
Study: 29601344

Group type: EXPERIMENTAL
Intervention: I‐InTERACT (10‐14 sessions)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Express (7 sessions)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 148
Study: 27655232

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stretch‐balance training
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 0
Study: 24485283

Group type: EXPERIMENTAL
Intervention: GET.ON Mood Enhancer Prevention training
Number of subjects: 406

Group type: COMPARATOR
Intervention: Online-based psychoeducation on depression
Number of subjects: 406
Study: 21808985

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis with alteplase (0.9 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 19935100

Group type: EXPERIMENTAL
Intervention: Light resistance exercise (LRO) at 30% of 1RM with partial occlusion
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Moderate resistance exercise (MR) at 70% of 1RM with no occlusion
Number of subjects: 7

Group type: COMPARATOR
Intervention: Partial occlusion without exercise (OO)
Number of subjects: 7
Study: 17931240

Group type: EXPERIMENTAL
Intervention: Collagen-gentamicin (260 mg gentamicin) sponges applied within the sternotomy before wound closure
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Intravenous isoxazolyl penicillin alone
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Collagen-gentamicin (260 mg gentamicin) sponges
Number of subjects: 2000
Study: 15536640

Group type: EXPERIMENTAL
Intervention: Clonidine (0.3 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Active placebo (loratadine 10 mg/day)
Number of subjects: 12
Study: 11907500

Group type: EXPERIMENTAL
Intervention: Finasteride, 1 mg/d
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 9468419

Group type: EXPERIMENTAL
Intervention: Flexible gastroscope
Number of subjects: 216

Group type: COMPARATOR
Intervention: Bronchoscope
Number of subjects: 216
Study: 7657952

Group type: EXPERIMENTAL
Intervention: Zidovudine therapy
Number of subjects: 0
Study: 2093381

Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg per day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Nifedipine (40 mg per day)
Number of subjects: 39
Study: 636560

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) or ASA-dipyridamole
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oral anticoagulants
Number of subjects: 90
Study: 30468356

Group type: EXPERIMENTAL
Intervention: Kinesio tape (KT) applied to the ankle and foot for a two-week period
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no Kinesio tape)
Number of subjects: 42
Study: 28187751

Group type: EXPERIMENTAL
Intervention: simeprevir 75 mg once daily + TMC647055 450 mg once daily/ritonavir 30 mg once daily + ribavirin 1000-1200 mg/day (Panel 1)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: simeprevir 75 mg once daily + TMC647055 450 mg once daily/ritonavir 30 mg once daily + ribavirin 1000-1200 mg/day (Panel 2-Arm 1)
Number of subjects: 70

Group type: COMPARATOR
Intervention: simeprevir 75 mg + TMC647055 450 mg/ritonavir 30 mg without ribavirin (Panel 2-Arm 2)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: simeprevir 75 mg + TMC647055 600 mg/ritonavir 50 mg with ribavirin (Panel 3-Arm 1)
Number of subjects: 70

Group type: COMPARATOR
Intervention: simeprevir 75 mg + TMC647055 600 mg/ritonavir 50 mg without ribavirin (Panel 3-Arm 2)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: simeprevir 75 mg + TMC647055 450 mg/ritonavir 30 mg + JNJ-56914845 30 mg once daily (Panel 4-Arm 1)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: simeprevir 75 mg + TMC647055 450 mg/ritonavir 30 mg + JNJ-56914845 60 mg once daily (Panel 4-Arm 2)
Number of subjects: 70
Study: 25525891

Group type: COMPARATOR
Intervention: Monovision
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Multifocal lenses (Air Optix Aqua)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both corrections
Number of subjects: 50
Study: 23694965

Group type: EXPERIMENTAL
Intervention: Primary nitinol stent placement
Number of subjects: 246

Group type: COMPARATOR
Intervention: Percutaneous transluminal balloon angioplasty
Number of subjects: 246
Study: 21199800

Group type: EXPERIMENTAL
Intervention: Low-fat, high-carbohydrate diet with intensive dietary counseling (target: 15% of calories from fat, 65% from carbohydrates)
Number of subjects: 4690

Group type: COMPARATOR
Intervention: Comparison group (standard dietary advice)
Number of subjects: 4690
Study: 19767063

Group type: EXPERIMENTAL
Intervention: Relative expression of ΔNp63α
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Debulking status
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: VEGF expression
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Disease progression risk per unit increase in ΔNp63α
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 56
Study: 17474134

Group type: EXPERIMENTAL
Intervention: HAART + CsA
Number of subjects: 15

Group type: COMPARATOR
Intervention: HAART
Number of subjects: 15
Study: 15141405

Group type: EXPERIMENTAL
Intervention: SMOF (alpha‐tocopherol‐enriched emulsion incorporating soybean, coconut, olive, and fish oils)
Number of subjects: 20

Group type: COMPARATOR
Intervention: LIPOVEN (soybean oil‐based emulsion)
Number of subjects: 20
Study: 11456079

Group type: EXPERIMENTAL
Intervention: Expert System (ES) intervention
Number of subjects: 4144

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 4144
Study: 9565419

Group type: EXPERIMENTAL
Intervention: Venipuncture (VP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Heel-lance with small lancet (SL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Heel-lance with large lancet (LL)
Number of subjects: 120
Study: 7887116

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 36

Group type: COMPARATOR
Intervention: Alfentanil combined with vecuronium or pancuronium
Number of subjects: 36
Study: 3060151

Group type: EXPERIMENTAL
Intervention: Betamethasone-dixyrazine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Betamethasone-dixyrazine (with doxorubicin)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Metoclopramide (with doxorubicin)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Betamethasone-dixyrazine (with cisplatin)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Metoclopramide (with cisplatin)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Metoclopramide (high-dose)
Number of subjects: 62
Study: 31197894

Group type: EXPERIMENTAL
Intervention: Daylight PDT with curettage (standard treatment)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Daylight PDT without curettage (1 hour MAL incubation)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Daylight PDT with curettage
Number of subjects: 25

Group type: COMPARATOR
Intervention: Daylight PDT without curettage
Number of subjects: 25
Study: 28186099

Group type: EXPERIMENTAL
Intervention: Intervention schools with redesigned play environments to encourage imaginative and independent free play by increasing opportunities for risk and challenge.
Number of subjects: 840

Group type: COMPARATOR
Intervention: Control schools that did not change their play environment.
Number of subjects: 840
Study: 26004075

Group type: EXPERIMENTAL
Intervention: Topical citicoline (OMK1®, Omikron Italia, 3 drops/day) over a 4-month period
Number of subjects: 56

Group type: COMPARATOR
Intervention: Beta-blocker monotherapy
Number of subjects: 56
Study: 23084029

Group type: EXPERIMENTAL
Intervention: Combination Z (oxygenated alcoholic beverage and oxygenated water)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Combination X (normal alcoholic beverage and normal water)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Combination Y (oxygenated alcoholic beverage and normal water)
Number of subjects: 15
Study: 21784297

Group type: EXPERIMENTAL
Intervention: Medication switch (SSRI or venlafaxine) with cognitive-behavioral therapy
Number of subjects: 334
Study: 19695543

Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 2469

Group type: COMPARATOR
Intervention: Heparin plus a GPI
Number of subjects: 2469
Study: 16542287

Group type: EXPERIMENTAL
Intervention: Propranolol +/‐ isosorbide mononitrate
Number of subjects: 71

Group type: COMPARATOR
Intervention: Nonresponders (no pharmacological therapy)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Reduction of HVPG
Number of subjects: 71

Group type: COMPARATOR
Intervention: No significant intervention
Number of subjects: 71
Study: 15584791

Group type: EXPERIMENTAL
Intervention: Positive aspects of caregiving (caregiving benefit)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control for caregiver demographic characteristics, contextual factors, and caregiving burden
Number of subjects: 217
Study: 11360771

Group type: EXPERIMENTAL
Intervention: Centripetal buildup technique with transparent matrices and reflective wedges
Number of subjects: 0

Group type: COMPARATOR
Intervention: Incremental technique (not explicitly detailed in the abstract)
Number of subjects: 0
Study: 9438229

Group type: EXPERIMENTAL
Intervention: Reboxetine (NARI)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Fluoxetine (SSRI)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study: 8342757

Group type: EXPERIMENTAL
Intervention: Intermittent bolus injection (Group B, n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Patient controlled administration with continuous infusion (Group P, n = 10)
Number of subjects: 20
Study: 3717846

Group type: EXPERIMENTAL
Intervention: Ultrasonic therapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Shortwave diathermy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Muscle relaxant drugs
Number of subjects: 120
Study: 28825352

Group type: EXPERIMENTAL
Intervention: Subcutaneous lidocaine plus 5% lidocaine cream (treatment group)
Number of subjects: 104

Group type: COMPARATOR
Intervention: 1 mL of 1% lidocaine subcutaneously (control group)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 104
Study: 27940715

Group type: EXPERIMENTAL
Intervention: Transcutaneous Bilirubinometry (TcB)
Number of subjects: 430
Study: 24695080

Group type: EXPERIMENTAL
Intervention: Supraglottic airway training (SGA group)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cricothyroidotomy training (CRIC group)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Final test response times (CRIC group)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Final test response times (SGA group)
Number of subjects: 23
Study: 22187440

Group type: EXPERIMENTAL
Intervention: Computer-selected ECGs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual-selected ECGs
Number of subjects: 0
Study: 20441723

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg to 50 mg/d)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 18583190

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation (three cycles of cisplatin and etoposide, followed by twice-daily radiation with concurrent carboplatin and vindesine)
Number of subjects: 524

Group type: COMPARATOR
Intervention: Control group (three cycles of cisplatin and etoposide, followed by surgery, then further radiotherapy)
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Pneumonectomy in interventional group
Number of subjects: 524

Group type: COMPARATOR
Intervention: Pneumonectomy in control group
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Overall survival (OS) and progression-free survival (PFS)
Number of subjects: 524
Study: 15964176

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic drugs (n = 32)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Conventional antipsychotic drugs (n = 36)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (n = 68 responders)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Nonresponders (n = 29)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Healthy control subjects (n = 59)
Number of subjects: 126
Study: 12025523

Group type: EXPERIMENTAL
Intervention: Psoas compartment block
Number of subjects: 60

Group type: COMPARATOR
Intervention: Inguinal paravascular block
Number of subjects: 60
Study: 10949771

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8956204

Group type: EXPERIMENTAL
Intervention: 5 mg oral formulation of melatonin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1416895

Group type: EXPERIMENTAL
Intervention: sulbactam-ampicillin (4 doses of 3 g ampicillin and 1.5 g sulbactam i.v. every 6 h)
Number of subjects: 99

Group type: COMPARATOR
Intervention: clindamycin-amikacin (4 doses of 600 mg clindamycin i.v. every 6 h and 2 doses of 500 mg amikacin i.v. every 12 h)
Number of subjects: 99
Study: 3858547

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) 3 mg/day orally for four days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2)
Number of subjects: 8
Study: 29781659

Group type: EXPERIMENTAL
Intervention: Extended nicotine deprivation (12‐24 hr smoking abstinence)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Minimal deprivation (2 hr smoking abstinence)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Continued smoking conditions
Number of subjects: 165
Study: 27257167

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline injection (placebo)
Number of subjects: 24
Study: 24378880

Group type: EXPERIMENTAL
Intervention: Group-based acceptance and commitment therapy (GACT)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Recommended pharmacological treatment (RPT; pregabalin + duloxetine)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Wait list (WL)
Number of subjects: 156
Study: 21646049

Group type: EXPERIMENTAL
Intervention: Mathieu repair with prepuce preservation (group I, n = 100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Traditional Mathieu repair with circumcision (group II, n = 100)
Number of subjects: 200
Study: 19695004

Group type: EXPERIMENTAL
Intervention: Reduction in leg pain
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Functional ability measured by Oswestry disability index (ODI)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Changes in leg pain over time
Number of subjects: 100
Study: 19278084

Group type: EXPERIMENTAL
Intervention: Oscillating/rotating power toothbrush (Oral-B Triumph Professional Care 9000)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Ultrasonic toothbrush (Ultreo)
Number of subjects: 25
Study: 15992696

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 1248

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 1248
Study: 12777959

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers
Number of subjects: 102

Group type: COMPARATOR
Intervention: Calcium channel blockers
Number of subjects: 102

Group type: COMPARATOR
Intervention: Beta blockers
Number of subjects: 102

Group type: COMPARATOR
Intervention: Alpha receptor blockers
Number of subjects: 102
Study: 11783183

Group type: EXPERIMENTAL
Intervention: Tangshen Mixture (TSM) + insulin
Number of subjects: 93

Group type: COMPARATOR
Intervention: Insulin alone (Control)
Number of subjects: 93
Study: 8904352

Group type: EXPERIMENTAL
Intervention: Dideuterated glucose as tracer, with non-adapted tracer priming dose
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dideuterated glucose as tracer, with appropriately matched priming dose
Number of subjects: 10

Group type: COMPARATOR
Intervention: NIDDM patients
Number of subjects: 10
Study: 31757518

Group type: EXPERIMENTAL
Intervention: d-amphetamine (20 mg)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 31373919

Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment (ART) discontinuation
Number of subjects: 1076

Group type: COMPARATOR
Intervention: ACTG treatment interruption trials (historical control, 91% male population)
Number of subjects: 1076
Study: 28863364

Group type: EXPERIMENTAL
Intervention: WBdiet (42 g total protein, 28 g whey, n=19)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: PBdiet (42 g various protein sources, n=19)
Number of subjects: 56

Group type: COMPARATOR
Intervention: CBdiet (high‐carbohydrate breakfast, 17 g protein from various sources, n=18)
Number of subjects: 56
Study: 27089862

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r)
Number of subjects: 33

Group type: COMPARATOR
Intervention: efavirenz (EFV)
Number of subjects: 33